Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 110

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 110
---
 our commercialization
operations in the U. S. following the Ayrmid License Agreement, we are not currently utilizing this space. Monthly rent is $23,600. The
lease expires in December 2025.

ITEM 4A. UNRESOLVED STAFF
COMMENTS

None.

ITEM 5. OPERATING AND FINANCIAL
REVIEW AND PROSPECTS

You should read the following discussion of our financial condition
and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report
on Form 20-F. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results
could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences
include those discussed below and elsewhere in this Annual Report on Form 20-F, particularly those in “ Item 3. Key Information - 
Risk Factors.” Our discussion and analysis for the year ended December 31, 2023 can be found in Item 5. “ Operating and Financial
Review and Prospects” of our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March
26, 2024, as amended on March 26, 2024 (File No. 001-35223).

We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. Our first approved product is APHEXDA (motixafortide), a novel peptide for the treatment of stem-cell mobilization
and solid tumors which, on September 8, 2023, was approved by the FDA for use in combination with filgrastim (G-CSF) to mobilize hematopoietic
stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. In October
2023, we out-licensed the rights to motixafortide for all indications in substantially all of Asia to Gloria, and in November 2024, we
out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors, to Ayrmid. As a result
of the November 2024 transaction, we shut down our independent commercialization activities in the United States and refocused our operations
on development activities in Israel in the fields of oncology (including solid tumors) and rare diseases, at a significantly